Form 4: Neogenomics Director Alison L. Hannah Reports Stock Transactions
SEC Form 4 Filing
Director Alison L. Hannah reports the release of restricted stock units and subsequent acquisition of common stock in Neogenomics.
Summary
- On August 10, 2024, Alison L. Hannah, a director of Neogenomics Inc., reported transactions involving the company's stock.
- Hannah acquired 11,336 shares of common stock upon the release of restricted stock units.
- Following the transaction, Hannah directly owns 118,769 shares of Neogenomics common stock.
- The reported transactions also involve derivative securities, including stock options with various exercise prices and expiration dates.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the filing simply reports transactions by a company director, which is a routine occurrence. There is no indication of positive or negative implications for the company's performance.
Positives
- The vesting of restricted stock units and subsequent acquisition of common stock could be seen as a positive sign, indicating confidence in the company's future performance.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. These filings are closely watched by investors to gauge sentiment and potential future stock performance.
Comparison to Industry Standards
- Comparing the option grants and vesting schedules to similar companies in the diagnostics and genomics space would provide context on whether these compensation packages are standard.
- Companies like Exact Sciences, Guardant Health, and Invitae could be used as benchmarks for comparison.
Stakeholder Impact
- The transactions reported may influence investor perception of the company's stock, but the direct impact on other stakeholders is likely minimal.
Key Dates
| Date | Description |
|---|---|
| 06/01/2019 | Date exercisable for stock options with an exercise price of $11.6 and an expiration date of 06/01/2023. |
| 06/01/2023 | Expiration date for stock options with an exercise price of $11.6. |
| 06/06/2020 | Date exercisable for stock options with an exercise price of $22.52 and an expiration date of 06/06/2026. |
| 05/28/2021 | Date exercisable for stock options with an exercise price of $28.54 and an expiration date of 05/28/2027. |
| 06/02/2022 | Date exercisable for stock options with an exercise price of $40.9 and an expiration date of 06/02/2028. |
| 06/10/2023 | Date exercisable for stock options with an exercise price of $8.1 and an expiration date of 06/10/2029. |
| 08/10/2024 | Date of transaction: release of restricted stock units and acquisition of common stock; Date exercisable for stock options with an exercise price of $14.82 and an expiration date of 08/10/2033. |
| 06/01/2025 | Date exercisable for stock options with an exercise price of $13.71 and an expiration date of 06/01/2034; Date exercisable for restricted stock units. |
| 06/06/2026 | Expiration date for stock options with an exercise price of $22.52. |
| 05/28/2027 | Expiration date for stock options with an exercise price of $28.54. |
| 06/02/2028 | Expiration date for stock options with an exercise price of $40.9. |
| 06/10/2029 | Expiration date for stock options with an exercise price of $8.1. |
| 08/10/2033 | Expiration date for stock options with an exercise price of $14.82. |
| 06/01/2034 | Expiration date for stock options with an exercise price of $13.71. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.